The Effect of a Charcoal Deactivation Pouch on Opioid Disposal After Cesarean Delivery

Geisinger Health

Status: Completed

Conditions: Cesarean Section Complications; Obstetric Pain; Pain, Acute; Opioid Misuse

Treatments: Other: Deterra activated charcoal pouch

Study type: Interventional

Funder types: Other

Identifiers

NCT05498025

2022-0487

Details and patient eligibility

About

Background: There is scarce literature investigating how patients dispose of unused opioid supplies after their cesarean postoperative pain has faded. The Office of the Surgeon General has identified research on the prevention of opioid use disorder area as well as research on the management of pain as a "Surgeon General Priority" that needs urgent investigation.

Hypothesis: At least 33% of postpartum women discharged home with an opioid prescription and a drug deactivation pouch will use the pouch to dispose of remaining opioids within 30 days of delivery.

Methods: This is a prospective single arm interventional pilot study.

Enrollment: 37 patients

Sex: Female

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age 18+ at time of enrollment, per ERM
• Delivered ≥26.0 weeks, per ERM
• Status post low transverse cesarean delivery, per ERM
• Physically located on labor & delivery and is postpartum day #1 or #2 at time of enrollment, per ERM
• Opioid prescription has been sent (per ERM) or will be sent (per obstetric team).

Exclusion criteria

• Positive urine toxicology anytime in pregnancy for non-prescription opioids, fentanyl, amphetamines, benzodiazepines, cannabinoids, LSD, or cocaine, per ERM.

• Buprenorphine or methadone Rx, per ERM

• Patient preferred communication language not English, per ERM

• Documented history, per ERM:

  • Cannabinoid use disorder
  • Hypnotic use disorder
  • Opioid use disorder
  • Stimulant use disorder
  • Fibromyalgia
  • Sickle cell anemia
  • Lumbar disc herniation
  • Multiple sclerosis
  • Trigeminal neuralgia
  • Active cancer
  • Complex regional pain syndrome
  • Systemic lupus erythematosus
  • Rheumatoid arthritis

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

37 participants in 1 patient group

Activated charcoal pouch

Experimental group

Description:

The patients in this arm will receive an activated charcoal pouch (Deterra Medium Pouch, UPC #: 850006727001, Verde Environmental Technologies, Minnetonka, MN) for disposal of their opioids after their cesarean delivery pain has resolved.

Treatment:

Other: Deterra activated charcoal pouch